Navigation Links
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
Date:4/23/2009

e IIb TBV TBV TBV RBV 20 mg/kg 25 mg/kg 30 mg/kg 800-1400mg n=67 n=70 n=68 n=70 TW4 Undetectable(1) 11 (16.4%) 10 (14.3%) 11 (16.2%) 8 (11.4%) TW12 Undetectable(1) 28 (41.8%) 29 (41.4%) 17 (25.0%) 22 (31.4%) TW48 Undetectable(1) 29 (43.4%) 21 (30%) 20 (29.4%) 23 (32.9%) SVR12 Undetectable(1) 19 (28.4%) 17 (24.3%) 14 (20.6%) 15 (21.4%) Anemia SVR12(2) 10 (14.9%)* 11 (15.7%)* 19 (27.9%) 23 (32.9%) (1) HCV RNA < 39 IU/mL (2) Anemia: hemoglobin < 10g/dL *P<0.05 vs. RBV

The most common adverse events during treatment were fatigue, nausea, flu-like symptoms, headache and diarrhea. The incidence rates for these adverse events among treatment arms were generally comparable except with respect to diarrhea, where incidence of diarrhea was approximately twice as common in patients receiving taribavirin compared to patients receiving ribavirin. However, the diarrhea was generally mild and not treatment limiting for taribavirin or ribavirin patients.

The Phase IIb trial is a U.S. multi-center, randomized, parallel, open-label study in 278 treatment-naive, genotype 1 patients evaluating taribavirin at weight-based doses of 20 mg/kg, 25 mg/kg, and 30 mg/kg per day in combination with pegylated interferon alfa-2b. The control group was administered weight-based dose ribavirin (800/1000/1200/1400mg daily) and pegylated interferon alfa-2b. Overall treatment duration is 48 weeks with a post-treatment follow-up period of 24 weeks.

About Taribavirin

Taribavirin is an investigational compound that has not been found by the Food and Drug Administration (FDA) or any other regulatory agency to be safe or effective in the diagnosis, mitigatio
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
2. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
3. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
6. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
7. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
8. Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... ... opinion piece published July 28 by the Washington Post, the conventional wisdom that ... not be accurate. While this system may work for some people, the author notes that ... on the individual and at what point that person is in their weight loss journey. ...
(Date:8/3/2015)... ... , ... Bayer has agreed to pay $56.9 million to set up a ... to have suffered an arterial blood clot including stroke and heart attack. The litigation ... has been ongoing for well-over five years. In 2009, lawsuits filed against Bayer involving ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... contract research organisations (CROs) for a slew of benefits, allowing them to gain ... operations, boost quality with cost-effective utilisation of resources, get access to innovation and ...
(Date:8/3/2015)... ... 2015 , ... A recent survey by the National ... believe people can positively affect their diabetes, few look beyond diet changes to ... changes was important. Far fewer participants mentioned the need for exercise (30%), maintaining ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
... for Provider Profiling, Predictive Modeling, Resource Management and ... DST Health Solutions today announced the ... DSTHS RiskAnalyzer(TM). RiskAnalyzer uses claims experience to determine ... under the Centers for Medicare and Medicaid Services ...
... QHR hospital clients received unexpected checks totaling nearly ... ranging from $65,000 to more than $750,000 - ... a unique and innovative partnership between the hospital ... Under the QHR/Gallagher Retro Insurance Program, hospital groups ...
... cadherin superfamily has a correlate relationship with the ... suggested that, unlike E-cadherin, N-cadherin may promote motility ... pathological significance of E-cadherin and N-cadherin expressions in ... led by Prof. Qing-Xia Fan from China detected ...
... 100,000 Swedes are under treatment with the blood-thinning drug ... makes the initiation of treatment a risky balancing act ... Uppsala University have developed a model for calculating the ... in the scientific publication New England Journal of ...
... PURCHASE, N.Y., Feb. 19 The PepsiCo Foundation ... Save the Children to help ensure the survival ... and Bangladesh, which together are home to 40 ... )With support from the PepsiCo Foundation, Save ...
... 19 Cardium Therapeutics (NYSE Alternext US: CXM) ... on January 23, 2009 has been accepted by ... Stock Exchange). (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )As ... from the staff of its current listing exchange ...
Cached Medicine News:Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 2Health News:DST Health Solutions Launches New RiskAnalyzer Software to Help Medicare Advantage Plans Manage Risk Adjustment 3Health News:QHR, Gallagher Partnership Yields More Thank $4 Million for QHR Hospital Clients 2Health News:Knowledge of genetics improves uncertain medication 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 2Health News:PepsiCo Foundation Announces Grant to Save the Children to Address Malnutrition in Developing Nations 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 2Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 3Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 4Health News:Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext US 5
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... , August 3, 2015 BiondVax Pharmaceuticals ... statistical analysis of results from a study which demonstrates that ... II trial which took place in 2012, provided participants with ... the time of the study- in particular the current newly ... the United States in 2015. ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively....
... The UC-Plus Solution knee is the ... articular surface replacement. Geometry of the articular ... allowance for anatomical variations, and achieves a ... and tibial components. Large, uninterrupted pockets of ...
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The modern design allows extremely sparing resections. The components exhibit an anatomical geometry t...
... Total Condylar Knee ... designed, tested and refined ... sophisticated computer graphics and ... features provide implant stability, ...
Medicine Products: